Podcast appearances and mentions of jude medical

Send us a textEpisode 119 discusses Executive Coaching with Susanne Biro. Susanne is a coach to C-suite and Executive Level Leaders.  She is also a senior facilitator, author, designer, TEDx and keynote speaker, and Forbes and CEO Magazine contributor.  For over two decades, she has worked internationally with senior level leaders.  Clients include top physician leaders at the Mayo Clinic, presidents of General Electric businesses, C-suite at the fastest growing digital agency in the world, CEO and entire SLT at numerous organizations, and executives responsible for billions of dollars and thousands of employees on multiple continents. She is the author of "I Want You To Win! Coaching Skills for Creative Leadership", a program designed to advance the coaching and leadership effectiveness of senior level leaders.   She is also co-author of "Together!" a two-day executive team development program, as well as the book "Unleashed! Leader as Coach" and the corresponding two-day workshop, which has been adopted by organizations like American Airlines, American Express, Eastman Chemical, General Electric, Group Health, Masco, Mayo Clinic, Salesforce.com, St. Jude Medical, among numerous others.    Episode Benefits:  You can expect to gain actionable insights and strategies towards Executive Coaching.  This Podcast series is targeted to Business Owners and C-Suite Executives.  It reflects my 34 years as a Business Owner and subsequent years as a Business Mentor and Consultant.  It focuses on the various subjects and topics to help you run a successful profitable business.  They are approximately 15-minutes long so you can listen while commuting.     Reach out to me to be put in contact with Susanne.   The Business of Business, topics are divided into 5 Categories: Management, Operations, Sales, Financial, and Personal. Support the showHelping You Run a Successful Profitable Business !For Business Consulting or to be a Podcast Guest - Contact me at: www.bcforg.comLinkedIn: https://www.linkedin.com/in/brian-fisher-72174413/

Margie Oleson, Ed.D. helps leaders crush their goals with better clarity and alignment among teams. As the founder and CEO of Oleson Consulting, she is a dynamic speaker and leadership expert who shares knowledge from her education and decades of experience in corporate America – from a variety of industries, including American Family Insurance, Ameriprise, Cargill, Catholic Charities, Ecolab, Securian Financial, St. Jude Medical, Target HQ, UCare, Lockheed Martin, and more. Leaders aren't set up to develop or adopt the right leadership skills and behaviors. Left to ‘make it up as they go', most learned from past leaders… who were also making it up! Dr. Oleson helps leaders develop the right leadership capabilities to grow and maintain high-performing teams, which is the single greatest strategic advantage for any organization.

William H. Sauer, MD, FHRS, CCDS, Brigham and Women's Hospital, is joined by Arif Elvan, MD, PhD, Klinikum Braunschweig, and Usha B. Tedrow, MD, MS, FHRS, Brigham and Women's Hospital, to discuss if Voltage mapping could identify the conducting channels potentially responsible for ventricular tachycardia (VT). Standard thresholds (0.5–1.5 mV) were established using bipolar catheters. No thresholds have been analyzed with high-density mapping catheters. In addition, channels identified by cardiac magnetic resonance (CMR) have been proven to be related to VT. https://www.hrsonline.org/education/TheLead https://doi.org/10.1016/j.hrthm.2024.04.074 Host Disclosure(s): W. Sauer: Honoraria/Speaking/Consulting: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific, Research: Medtronic   Contributor Disclosure(s): A. Elvan: Honoraria/Speaking/Consulting: Abbott Medical U. Tedrow: Honoraria/Speaking/Consulting/Teaching: Medtronic, Biosense Webster, Inc., St. Jude Medical, Thermedical, Boston Scientific, Baylis Medical Company   This episode has .25 ACE credits associated with it. If you want credit for listening to this episode, please visit the episode page on HRS365: https://www.heartrhythm365.org/URL/TheLeadEpisode95

This week, we revisit our interview with Keith Grossman. He currently serves as Chairman of Nevro Corp. (NVRO), Vice-Chairman of Alcon, Inc. (ALC), and Lead Director of Outset Medical, Inc. (OM). Previously, Keith was the CEO and President of Nevro. Keith has over 40 years of experience in the medical device field. He served most recently, and for the second time, as the President, Chief Executive Officer, and director of Thoratec Corporation, leading up to its 2015 sale to St. Jude Medical.   Before Thoratec, he served as President, Chief Executive Officer, and director of Conceptus, a women's health medical device company, leading up to its sale to Bayer Healthcare. Before Conceptus, Keith served as managing director of TPG (Texas Pacific Group), a private equity firm, and was a member of its healthcare investment team. Prior to TPG, Keith served as Thoratec's President, Chief Executive Officer, and director for the first ten years of its growth as a commercial company.  Keith was chronicled in the book “Executive Intelligence: What All Great Leaders Have”, was named among the “Business Leaders to Watch” and the “40 Under 40” lists in the Bay Area and was awarded the Lifetime Achievement Award by his Medical Device CEO peers. Keith received a B.S. in life sciences from The Ohio State University and an M.B.A. from Pepperdine University.

With Susanne Biro, a coach to C-suite and executive-level leaders. She is also a senior facilitator, executive development program designer, author, Forbes and CEO Magazine contributing writer, and a TEDx and keynote speaker. For over two decades, Susanne has worked internationally with senior-level leaders in some of the world's best companies. Whether coaching one-on-one or authoring, designing, and delivering leadership programs, her passion is the same: to help leaders reach their next level. She is the Founder of Inner Life Leadership, an app for business professionals who want to reach an unprecedented level of personal understanding and corresponding leadership (and life) success. She is also the author of the “I Want You To Win!” Coaching Skills for Creative Leadership, co-author of “Together” Executive Team Development, and the book Unleashed! Leader as Coach, adopted by organizations like General Electric, American Express, St. Jude Medical, Celgene, Mayo Clinic, salesforce.com, and numerous othersJoin us in our conversation as Susanne shares powerful insights on leadership, self-awareness, and the mindset shifts that drive success. She discusses why even top executives struggle with self-doubt, how character and integrity can be your greatest advantage in business, and the simple yet transformative habits that can elevate your performance. Tune in to learn how to lead with confidence, cultivate a mindset that serves you, and build a business—and life—you truly love.To listen to the podcast and access the show notes and any other resources mentioned in this episode, visit us at www.legalwebsitewarrior.com/podcast.

William H. Sauer, MD, FHRS, CCDS, Brigham and Women's Hospital is joined by Isabella Alviz, MD, Brigham, and Women's Hospital, and Usha B. Tedrow, MD, MS, FHRS, Brigham and Women's Hospital to discuss how patients with ventricular tachycardia and ischemic cardiomyopathy are at high risk for adverse outcomes. Catheter ablation is commonly used when antiarrhythmic drugs do not suppress ventricular tachycardia. Whether catheter ablation is more effective than antiarrhythmic drugs as a first-line therapy in patients with ventricular tachycardia is uncertain. https://www.hrsonline.org/education/TheLead https://www.nejm.org/doi/full/10.1056/NEJMoa2409501 Host Disclosure(s): W. Sauer: Honoraria/Speaking/Consulting: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific, Research: Medtronic   Contributor Disclosure(s): I.  Alviz: Nothing to disclose. U. Tedrow: Honoraria/Speaking/Consulting/Teaching: Medtronic, Biosense Webster, Inc., St. Jude Medical, Thermedical, Boston Scientific, Baylis Medical Company This episode has .25 ACE credits associated with it. If you want credit for listening to this episode, please visit the episode page on HRS365 https://www.heartrhythm365.org/URL/TheLeadEpisode90

In this episode of AbbottTalks, Kartik Sundareswaran, PhD, divisional VP, global clinical and regulatory affairs, Abbott Heart Failure, discusses Abbott's pioneering work in heart failure care, focusing on technologies that improve outcomes and empower earlier interventions. Sundareswaran's path to MedTech began with a shift from computer engineering to biomedical research, where his early work studying blood flow patterns in children with congenital heart disease sparked a passion for solving cardiovascular challenges. This passion led him to roles at Thoratec, St. Jude Medical, and ultimately Abbott, where he has spent years advancing heart failure care. The conversation highlights Abbott's CardioMEMS™ Heart Failure System, a device enabling remote pulmonary artery pressure monitoring to reduce hospitalizations, and the HeartMate 3 LVAD, which provides life-extending support for patients with advanced heart failure. Sundareswaran also discusses the new TEAM-HF clinical trial, which combines CardioMEMS and HeartMate 3 to identify patients earlier and deliver timely, effective interventions. This conversation comes to you courtesy of our episode sponsor, Tecan Group Ltd. To learn more about how Tecan works with medical device companies, visit: https://partnering.tecan.com/ Thank you for listening to the AbbottTalks Podcast. Tune in and subscribe to DeviceTalks on all major podcast channels to never miss an episode.

Send us a textIn this first episode of a special series on tools for accelerating engineering, host Aaron Moncur engages in a thought-provoking conversation with TJ Strang, an experienced leader in the medical device industry. Together, they explore the challenges that often hinder engineering projects and share insights on how to overcome them. The discussion covers a wide range of topics, focusing on ways to enhance efficiency, support team development, and improve communication within engineering teams.Main Topics:Common bottlenecks in engineering projectsBalancing help-seeking and independent learning for junior engineers The role of psychological safety in engineering teamsLeadership's impact on engineering project speedTools and technologies for accelerating engineeringUnconventional approaches to expediting engineering processesOptimizing communication for faster engineeringAbout the guest: TJ Strang, is a distinguished leader in the medical device industry. With a career spanning over two decades at companies like Abbott, and St. Jude Medical, and Acutus Medical, he has led groundbreaking projects in electrophysiology, cardiac rhythm management, and leadless pacemakers. TJ's expertise in assembling and leading top-tier R&D teams, driving products from concept to market, and overall engineering innovation makes him the perfect guest to start this series. TJ currently serves as VP of Engineering at Atraverse Medical, which is developing cutting-edge left-heart access technologies.Links:TJ Strang - LinkedInAbout Being An Engineer The Being An Engineer podcast is a repository for industry knowledge and a tool through which engineers learn about and connect with relevant companies, technologies, people resources, and opportunities. We feature successful mechanical engineers and interview engineers who are passionate about their work and who made a great impact on the engineering community. The Being An Engineer podcast is brought to you by Pipeline Design & Engineering. Pipeline partners with medical & other device engineering teams who need turnkey equipment such as cycle test machines, custom test fixtures, automation equipment, assembly jigs, inspection stations and more. You can find us on the web at www.teampipeline.us

Steve Gompertz discusses the complexities of navigating the regulatory landscape in the medical device industry. He shares insights on the evolution of global regulations, the balance between innovation and quality control, and strategies for developing effective quality management systems for companies of all sizes. Main Topics:Regulatory compliance in medical devicesTailoring quality management approaches for small vs. large companiesThe core components of a quality system and its evolution over timeEmerging trends in medical device regulations, such as AI and cybersecurityImproving quality management systems and achieving regulatory complianceSteve Gompertz is a highly experienced leader in quality systems management and regulatory compliance, currently serving as a partner at QRx Partners. With a career spanning over 30 years, he has held significant roles in various companies, including Pelican Biothermal, St. Jude Medical, Boston Scientific, and Medtronic. At QRx Partners, Steve specializes in quality systems development, project management, and engineering automation, helping companies navigate complex regulatory environments and enhance their quality management systems​Links:Steve Gompertz - LinkedInQRx Partners WebsiteAbout Being An Engineer The Being An Engineer podcast is a repository for industry knowledge and a tool through which engineers learn about and connect with relevant companies, technologies, people resources, and opportunities. We feature successful mechanical engineers and interview engineers who are passionate about their work and who made a great impact on the engineering community. The Being An Engineer podcast is brought to you by Pipeline Design & Engineering. Pipeline partners with medical & other device engineering teams who need turnkey equipment such as cycle test machines, custom test fixtures, automation equipment, assembly jigs, inspection stations and more. You can find us on the web at www.teampipeline.us

Joe Moak shares his experience with the podcast working at high-profile companies such as Apple & Sonos, and also gives us a glimpse into “the best place he has ever worked” (Maestro PD). Companies are always looking for those elusive “A” players to join their teams, and it is very clear that Joe qualifies under that definition.Joe Moak earned his mechanical engineering degree at California Polytechnic State University-San Luis Obispo.To sum up, Listen to this episode to learn all these!Main Topics:Working at AppleDesigning for manufacturing toleranceProduct development challengesInterviewing techniquesDesign processes,Project management best practicesAbout the guest: Joe Moak, founder and chief engineer at Maestro PD, a product design and engineering firm. Joe also worked at Apple, Sonos, St. Jude Medical, and other companies.Links:Joe Moak - LinkedInMaestro PDAbout Being An Engineer The Being An Engineer podcast is a repository for industry knowledge and a tool through which engineers learn about and connect with relevant companies, technologies, people resources, and opportunities. We feature successful mechanical engineers and interview engineers who are passionate about their work and who made a great impact on the engineering community. The Being An Engineer podcast is brought to you by Pipeline Design & Engineering. Pipeline partners with medical & other device engineering teams who need turnkey equipment such as cycle test machines, custom test fixtures, automation equipment, assembly jigs, inspection stations and more. You can find us on the web at www.teampipeline.us

In this episode of Medsider Radio, we had an insightful discussion with Dr. Eric Fain, CEO and President of Procyrion — a startup developing an advanced percutaneous mechanical circulatory support device for patients with chronic heart failure.  Eric began his career at Ventritex, a startup focused on implantable defibrillators. Over the next 30 years, and through the company's acquisition by St. Jude Medical, he has held a number of leadership roles overseeing global sales, marketing, R&D, and clinical, eventually becoming the Group President via St. Jude's exit to Abbott. In this interview, Eric shares his expertise in managing startup finances, attracting investors through strategic planning, drawing up clear clinical roadmaps, and engaging with payers to catalyze commercialization. Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume V. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Dr. Eric Fain.

Janice Y. Chyou, MD, FHRS, Icahn School of Medicine at Mount Sinai, is joined by guest Christine M. Albert, MD, MPH, FHRS, Cedars-Sinai Medical Center and Marina Cerrone, MD, NYU School of Medicine to discuss how Electrocardiogram (ECG) abnormalities have been evaluated as static risk markers for sudden cardiac death (SCD), but the potential importance of dynamic ECG remodeling has not been investigated. In this study, the nature and prevalence of dynamic ECG remodeling were studied among individuals who eventually suffered SCD. https://www.hrsonline.org/education/TheLead https://pubmed.ncbi.nlm.nih.gov/37956651/ Host Disclosure(s): J. Chyou: Honoraria/Speaking/Consulting: McGraw-Hill, American Heart Association, Membership, Advisory Committee: American Heart Association Contributor Disclosure(s): C. Albert: Research: Abbott, Roche Diagnostics, St. Jude Medical, NIH, Honoraria/Speaking/Consulting: Boston Scientific, Medtronic, Element Services, Inc., Illumina, Novartis M. Cerrone: Research: American Heart Association, Honoraria/Speaking/Consulting: StrideBio, Medtronic Inc., BioMarin, Inc., Abbott Medical This episode has .25 ACE credits associated with it. If you want credit for listening to this episode, please visit the episode page on HRS365 https://www.heartrhythm365.org/URL/TheLeadEpisode55

This week, we welcome back Keith Grossman. Keith has been a leader in the medical technology industry for more than 35 years. He is currently the Chairman of the Board of Nevro Corporation (NVRO), where he was previously President and CEO from 2019 through April 2023. Prior to Nevro, he was named President and CEO of Thoratec Corp. (THOR) for the second time in 2014. He led the company's return to growth, a 2.5x increase in company value, and its $3.4 billion acquisition by St. Jude Medical in 2015. He previously served as the CEO, President, and Director of Conceptus, Inc. (CPTS) from 2011 to 2013, where he took the company from negative sales growth to over 20% growth, tripled EBIDTA, and led the company's sale to Bayer Healthcare for over $1.1 billion, a 3x increase in the company's value before his arrival. Prior to Conceptus, Keith served as managing director of TPG (Texas Pacific Group), a private equity firm, as a member of its healthcare investment team. Prior to TPG, Mr. Grossman served as Thoratec's President, Chief Executive Officer, and director for the first ten years of its growth as a commercial company. Prior to Thoratec, he held a number of commercial and general management roles with companies, including SulzerMedica and American Hospital Supply Corp. He currently also serves as Vice Chairman of Alcon, Inc., and is on the board of Outset Medical, Inc. and previously served as a member of the Board of directors of Intuitive Surgical, Inc., Kyphon, Inc., ViewRay, Inc., Zeltiq, Inc, and a number of privately held medical device companies. Keith received a B.S. in life sciences from The Ohio State University and an M.B.A. from Pepperdine University.

William H. Sauer, MD, FHRS, CCDS of Brigham and Women's Hospital, is joined by Uyanga Batnyam, MD of the University of Washington and Usha B. Tedrow, MD, MS, FHRS of Brigham and Women`s Hospital to discuss the risks of radiofrequency catheter ablation for ventricular arrhythmias include emboli and bleeding complications but data on antithrombotic regimens are limited and guidelines do not specify a systematic approach. This study sought to assess embolic and bleeding complications in relation to pre- and postperiprocedure antithrombotic regimens. Stroke is a rare complication of radiofrequency catheter ablation for ventricular arrhythmia using ASA 325 mg/d as a minimal postprocedure regimen with more potent regimens for selected patients. https://www.hrsonline.org/education/TheLead https://www.jacc.org/doi/abs/10.1016/j.jacep.2023.10.011 Host Disclosure(s): W. Sauer: Honoraria/Speaking/Consulting Fee: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific; Research (Contracted Grants for PIs Named Investigators Only): Medtronic Contributor Disclosure(s): U. Batnyam: No relevant financial relationships with ineligible companies to disclose.  U. Tedrow: Honoraria/Speaking/Consulting: Medtronic, Inc., Biosense Webster, Inc., St. Jude Medical, Thermedical, Boston Scientific, Baylis Medical Company “This episode has .25 ACE credits associated with it. If you want credit for listening to this episode, please visit the episode page on HRS365 https://www.heartrhythm365.org/URL/TheLeadEpisode49

In this episode of Medsider Radio, we had a fascinating discussion with Daniel Powel, CEO of Spark Biomedical, the company behind Sparrow Ascent, a drug-free wearable device to combat opioid withdrawal symptoms. It is also advancing neurostimulation technology to address Neonatal Opioid Withdrawal Syndrome. Daniel found his true passion in medical devices, specifically neurostimulation, in 2006 and has since launched multiple products in the space for companies like St. Jude Medical, LivaNova, and Getinge. He co-founded Spark Biomedical in 2018, which now has two FDA-cleared devices to treat opioid addiction.In this interview, Daniel shares key insights from his journey: the importance of testing ideas and creating a MVP, diversifying funding sources, and how to make informed regulatory decisions.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Daniel Powell.

In this episode of Medsider Radio, we had an insightful conversation with Dave Rosa, President and CEO of NeuroOne, a company developing high-definition, minimally invasive neurology devices utilizing unique thin-film electrode technology. Dave brings over three decades of experience in the medical device industry. His career spans several key roles at major firms like C.R. Bard, Boston Scientific, and St. Jude Medical, focusing on marketing, product development, strategy, and commercialization. Dave has several medical device patents to his name, has served on numerous corporate boards, and raised over $200 million in the capital markets. He holds an MBA from Duquesne University and a BS in Commerce and Engineering from Drexel University.In this interview, Dave discusses critical strategies to secure initial capital even before early development and regulatory milestones are achieved, how to leverage networks to connect with potential investors; and the importance of assembling a supportive and experienced team, including board members. Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the recently launched Medsider Mentors Volume IV. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Dave Rosa.

Join us as we dive into Margie Oleson's fascinating journey—from navigating chaos and ineffective leadership to cultivating a passion for structure. Discover how she transformed her experiences into a commitment to leader effectiveness and team development. With decades of experience in corporate America and a Doctorate in Organization Development, Margie Oleson brings a wealth of knowledge across diverse industries such as Aerospace, FinTech, Retail, Manufacturing, Agriculture, Financial Services, and Health Care. Her expertise extends to organizations of all sizes, ranging from small and medium enterprises to very large entities in government, military, social services, and Fortune 500 companies—both for-profit and nonprofit. Margie has supported leaders in diverse industries, such as Target, Cargill, Ameriprise Financial, Ecolab, Securian Financial, Lockheed Martin, UCare, St. Jude Medical, American Family Insurance, and others. Focusing on organizational dynamics, she collaborates with senior leaders, enabling them to transform into cohesive, high-performing teams, resulting in elevated performance within their respective teams. Connect with Margie online: Website | LinkedIn

Prashanthan Sanders, MBBS, PhD, FHRS, of University of Adelaide is joined by guests Han S. Lim, MBBS, PhD, FHRS, of Austin and Northern Health, University of Melbourne, and Venkatakrishna N. Tholakanahalli, MD, FHRS, of Minneapolis VA Health Care System to discuss Atrioesophageal Fistula Rates Before and After Adoption of Active Esophageal Cooling During Atrial Fibrillation Ablation. This institutional review board (IRB)-approved study was a prospective analysis of retrospective data, designed before collecting and analyzing the real-world data. The number of AEFs occurring in equivalent time frames before and after adoption of cooling using a dedicated esophageal cooling device (ensoETM, Attune Medical) were quantified across 25 prespecified hospital systems. AEF rates were then compared using generalized estimating equations robust to cluster correlation. A total of 14,224 patients received active esophageal cooling during RF ablation across the 25 hospital systems, which included a total of 30 separate hospitals.   https://www.hrsonline.org/education/TheLead https://www.sciencedirect.com/science/article/pii/S2405500X23006734?via%3Dihub https://drive.google.com/file/d/1pbrQyW9Yqf-da0KceRueP01kS9WIgwmK/view (Visual Aid)   Host Disclosure(s): P. Sanders: Research (Contracted Grants for PIs Named Investigators Only): Boston Scientific, Abbott, Medtronic, PaceMate, Becton Dickinson, CathRx; Advisory Committee Membership: Medtronic, Boston Scientific, PaceMate, CathRx   Contributor Disclosure(s): H. Lim: No relevant financial relationships with ineligible companies to disclose. V. Tholakanahalli: Honoraria/Speaking/Consulting Fee: Kobra Medical, Imricor; Research (Contracted Grants for PIs Named Investigators Only): Biosense, St. Jude Medical, Cardailen

Jason T. Jacobson, MD, FHRS, of Westchester Med Center-New York Med College is joined by guests, David S. Frankel, MD, FHRS, of the Hospital of the University of Pennsylvania, and Usha B. Tedrow, MD, MS, FHRS, of Brigham and Women's Hospital, to discuss substrate mapping altering ventricular tachycardia inducibility. The authors performed a retrospective analysis of the reproducibility of programmed stimulation for the first induction of ventricular tachycardia in those with and without intervening voltage mapping. This was study was not randomized. All subjects had 2 rounds of programmed stimulation separated in time. One group underwent intracardiac echocardiographic mapping in between attempts while the other underwent substrate mapping. The authors found a change in the results of programed stimulation (to either a different VT, or to non-inducibility) more frequently after substrate mapping.   https://www.hrsonline.org/education/TheLead   Host Disclosure(s): J. Jacobson: Honoraria/Speaking/Consulting Fee: American College of Cardiology, Zoll Medical Corporation; Research (Contracted Grants for PIs Named Investigators Only): Abbott, Phillips; Stocks (Privately Held): Atlas 5D   Contributor Disclosure(s): D. Frankel: Honoraria/Speaking/Consulting Fee: Biosense Webster, Inc., Medtronic, Abbott Medical, Stryker, Boston Scientific U. Tedrow: Honoraria/Speaking/Consulting Fee: Biosense Webster, Inc., St. Jude Medical, Thermedical, Medtronic, Boston Scientific, Baylis Medical Company

Heart disease is the leading cause of death in America and notoriously goes undiagnosed in rural settings. Our next guest is utilizing AI technology to help provide life-saving early detection efforts to rural communities. This week we are talking with Chuck Vivian, the Vice President of Sales with Caption Health a part of GE Healthcare. Chuck will discuss why he went into rural healthcare and the exciting advancements in AI he and his team are making to address heart failure. “I'm not naïve enough to think that we can make heart failure go away, but I'll be darned if we can't bend this curve with technology.” “I'm not naïve enough to think that we can make heart failure go away, but I'll be darned if we can't bend this curve with technology.”  -Chuck Vivian Chuck has had the privilege of building an extraordinary track record in senior commercial executive roles with U.S. Surgical and Computer Motion Surgical Robotics. As a consultant, Chuck leveraged his experience to serve the needs of companies such as St. Jude Medical, Zimmer, Boston Scientific, Otsuka America, Novo Nordisk, Rita Medical, Virtual Radiologic, and Abbott Vascular among others. While he was fortunate to work on critical projects for these great companies, he is grateful for the exponential growth that they provided him. Chuck could not have learned so much, from so many, without the unique and challenging engagements that he was entrusted to address. If you are interested in learning more about Caption Health's AI technology, follow the link: ​Caption AI Product Demo | AI-Guided Ultrasound System - YouTube

Daniel Powell, a 20-year veteran in the medical device community, is the CEO and co-founder of Spark Biomedical and developer of the Sparrow Therapy System. In this episode, he shares about opioid addiction and how Spark's device helps alleviate withdrawal symptoms for those in recovery, his passion for deep brain stimulation, and how he almost gave up on entrepreneurship after his first small business venture ended.  Guest links: https://www.sparkbiomedical.com/  Charity supported: Threads of Love Interested in being a guest on the show or have feedback to share? Email us at podcast@velentium.com.  PRODUCTION CREDITS Host: Lindsey Dinneen Editor: Tim Oliphant Producer: Velentium   SHOW TRANSCRIPT Episode 003 - Daniel Powell Lindsey Dinneen: Hi, I'm Lindsey with Velentium and I'm talking with MedTech industry leaders on how they change lives for a better world. Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello and welcome to the Leading Difference Podcast. I'm your host Lindsey, and I am excited to introduce you to my guest today, Daniel Powell. Daniel, a 20 year veteran in the medical device community, is the CEO and co-founder of Spark Biomedical, and developer of the Sparrow Therapy System, which is an FDA cleared medical device that delivers non-invasive neurostimulation to alleviate opioid withdrawal. Daniel, thank you so very much for being here today. I am so delighted to have you. Daniel Powell: Thank you, Lindsey. It's a pleasure to be here, too. Lindsey Dinneen: Awesome. Well, I was wondering if you don't mind starting with just a little bit about your background. What's your career path been like? How did you get into this space? Daniel Powell: That's a great question and I, I definitely do not have a typical path here. I took the scenic route, I would say, to MedTech. I graduated from Texas A&M with a business degree, and my first job was an accounts receivable at electronic data systems at Ross Perot's old company in Plano, Texas. I was very interested in technology and I kind of spent the first. 10 years of my career trying to figure out what career I wanted. So I bounced around. I had a great opportunity to be a consultant for KPMG. I did Y2K consulting, so we sat around telling everybody it was gonna be the end of the world and it wasn't. And then I got the crazy idea to start my own internet cafe for gamers because I really wanted to be self-employed and do my own thing. And I always say that was a fantastic way to lose a lot of money. And I swore I'd never be an entrepreneur again. I was like, I'm just gonna go to work, take a paycheck, keep my head down. And my next job was at St. Jude Medical in the neurostimulation business. And so I got a great opportunity to go into the the engineering side of all things. Even though I had a business background, I was pretty good with soft, actually, I was mediocre with software. But I got an opportunity to do requirements analysis, so, what does the product need to do to meet the user's needs? And I was really good at that and it really started a fantastic career and I really didn't get how excited I would be about the medtech industry cuz I, really was just looking for a job to not be losing money as a self-employed game store owner. And I remember going into training, they put me in sales training and they sat there and explained how putting electrical stimula on or near the spinal cord would alleviate pain in this world of neurostimulation. And I would say I fell in love with it immediately and could never get enough learning how the mechanism of action works, all the different modalities of this type of therapy. And it's set me now here for a 20 year run, where I'm just as in love with neurostimulation today as I was back then. Lindsey Dinneen: Oh my goodness. Wow. Well, I love your story and I love the fact that you come at this from a very interesting background and, oh my goodness, your swearing off entrepreneurial endeavors and then of course-- "never say never," I guess. Right? Daniel Powell: Well, when Spark came about, I'd actually gone to work for a startup that failed where I met my co-founders and I hadn't been paid in nine months. But I got along with my co-founder so well, and it was the worst time in the world to start a business. So you can imagine the conversation with my wife was like, "I know I haven't brought home a paycheck in nine months and I'm coming out of a failed startup. But what if we started our own company?" But we've never regretted it. It's just been an amazing four and a half years. Lindsey Dinneen: Oh my gosh. That's amazing. Well, I would love, if you don't mind sharing about what you're up to now and this amazing new venture that you're on, and how has that all come about? I mean, obviously you must have had some highs and lows even there, so I'd love to hear the story of Spark. Daniel Powell: Yeah. It's been quite a journey. So what was interesting is my two co-founders, Navid and Alejandro, were exploring how to do auricular nerve stim, so stimulating the cranial nerves around the ear. And we had a wide selection of different things we could go after. Navid's PhD work was in vagus nerves stim for stroke recovery, and we know vagus nerves stim works for depression and epilepsy and a wide range of disease states. But what really set us in motion as we saw another product, just by happenstance, a friend of mine was selling trans magnetic stim to a psychiatrist who had used acupuncture needles to alleviate withdrawal-- an an electrified acupuncture needle. So they were kind of creating a way of delivering electrical stim to the nervous system. And they showed me a video of a young lady going through withdrawal and a time lapse over 30 to 60 minutes and this young lady went from clearly uncomfortable, snot running down her face, squirming in her chair. You can tell when someone's in absolute misery and she was an opioid withdrawal. And then 60 minutes later there's this beautiful young lady sitting in the chair laughing and having a conversation and there's a twinkle in her eye. And I was sold. I was like,, this is what we're gonna go after cuz our product doesn't use needles. I think we could build a better mouse trap. And then also kind of the concept was we know there's an FDA path and we know there's a clinical path and we know the technical path. So the big three pillars of building a medical device company were relatively low risk. And so we talked about it and then we formed the company and we spent the next three months trying to kill it. " Does this make sense? Do we really want to do this?" And just every time we turn around, another door opened. Another opportunity presented itself. A clinical partner came online, somebody came to us and we just were continually encouraged to keep persevering. And we developed our first generation device, put it in clinical trials in Austin, Texas at Recovery Unplugged. Everything from building the quality management system to building the product-- everything we were doing for the first time. But you know we persevered through that. Everything took twice as much money and twice as long as we expected. All along the way, everything continues to take twice as long and twice as much money, at least. And then when we finished, we took the product to the FDA. And then that's when the real challenges began. We did a pre-submission. So you go to the FDA ahead of time and you go, "we think this is all the things we should do, and if we do 'em, you'll approve the product." And the FDA then gives you feedback and you take that feedback and then you go execute. And when we showed back up at the FDA, they said no, "we changed our mind." And we're, just like we're outta money we're, betting on this working. We did everything right. We followed the directions. So we started throwing money at consultants and onboarding people, and we onboarded somebody who, as a consultant, had just come out of the neuro division to help us fight, and finally got the product approved six months later than it should have. But that was an exciting day. Well, it wasn't a day, it was a night. The FDA has a clock and they have to deliver all their documents and their decisions and everything before the timer runs out. And the timer ran out Saturday night at 11 o'clock, January the 2nd. So a holiday weekend, and we got the approval about 30 minutes before the clock ran out, which means on a holiday weekend, in the evening, people at the FDA were having to route this thing around and, and sign off on documents. I was like, "thanks, guys." Lindsey Dinneen: Oh my word. But what a brilliant way to start the new year? Daniel Powell: Yes, it was, and that was two years ago. And we spent the first year really trying to test different business models. Well, really spent both the first and second year just figuring out the business model. And all of us, our entire careers we'd sold into doctors and neurologists and neurosurgeons and hospital systems. And selling into addiction rehabilitation is a very different animal. It's funny cuz I would have a neurosurgeon when I was doing deep brain stimulation with St. Jude Medical, " where's all your clinical evidence? I wanna see four or five, six papers" and "where's your proof?" And then we went into addiction, everybody was like, "yeah, I totally believe you, this works." We're like, "okay, well we do have clinical proof also," but they would hit the "I believe" button really quick. But integrating it into the practice has been a real challenge. And it didn't help that we started selling right in the middle of Covid, so we couldn't get appointments. But importantly, what we saw in rehab was, rehab is a tough business and doesn't pay great. They run on rough margins, and in the middle of Covid, a nurse could work at a rehab facility or get a job at a hospital and make four or five times the hourly rate. So that they had staff turnover. So it's, it was a real tough time to launch a product into the rehabilitation space. Our journey has brought us to now where we have our second generation product about to be approved by the FDA. Really just took all the lessons on usability, accessibility. Everything we saw with the first gen, and we really did have like kind of an MVP, a minimally viable product. So we took all of our lessons to really make a very much more consumer focused, industrial design on the case and everything, and then get our costs of the goods way down as we get ready to ramp. And we're really focused on bringing this to telehealth and so our journey from here, at the time of recording this with you, is Covid changed everything. If I had a business model in 2019 that said "I'm going to deliver at-home detox services with telehealth support," it would've been ridiculous. And then two years later, it's "of course that's the way you're gonna do it." It's changed all the laws, changed reimbursement, changed acceptance. It really is a great opportunity to meet people where they want to detox. Nobody really wants to go into a center and be away from their family and the comforts of life and their dog and the pet and the kids for seven days. And for some people that's the best thing for them to do. But for a lot of other people, they want to get well-- and we can dig into the opioid epidemic and the realities of it as opposed to maybe what a lot of people's preconceptions are-- but most people really want to get off their dependence or addiction to opioids. But going through the detox process is the giant barrier. You're gonna go through seven days of absolute hell. And so being able to let people stay at home through that process, we think, is really the way to go for the future here. So we're betting a lot on it. Lindsey Dinneen: Yeah. Well, there's a lot to unpack in that story. That is such a great story. Thank you for sharing that. So one thing that stands out, for sure, is you were saying that there is quite a bit of stigma around addiction and treatment. How do we get past that? How are you and Spark and the different products, how can that help alleviate some of the challenges with getting healthy again and overcoming that addiction? Daniel Powell: Yeah, we definitely as a company want to actually not just alleviate withdrawal-- that's a minor piece-- but really be a solution for battling the opioid epidemic. So, the first step is to remove the stigma, stigmatization about it. At the RX Summit-- which is a big summit that has a lot of political leaders and industry leaders and pharmaceutical companies and everything that come together every year-- they put doctor's notes of patients with diabetes and then patients who had an assumed opioid overdose incident. And while the notes side by side were factually accurate, the tone of dismissal was just evident, you know, one was a bad patient and one was as patient you could have sympathy for. And it was really shocking to see that bias. I've heard the stories where the paramedics will use an extra large gauge needle to administer IV fluids on an overdose patient just so they hurt in the morning, just so that arm really hurts. And it's just, oh my gosh, you kind of back up and you go, "how inhumane? How inhumane is that?" And so best I could do is I'll get on a podcasts like this and talk about it openly, but you know, in my own family, my nephew was addicted to heroin, this is my brother's kid. And I have permission to talk about it. In fact, now that he is in recovery, he talks about it all the time. So he said, absolutely I could reference him. And we didn't talk about it and he went to prison and I didn't ask about him and it was shameful, and my brother didn't want to talk about it and his wife didn't want to talk about it, because there's this failing of one of their children. And when I started this company, I actually called my brother one day and I said, how much had treatment cost him. Cause I was trying to get an idea of what to price this product at and would he buy it, and he had spent well over six figures. And you realize families trying to save their loved ones were spending huge amounts of money and we just started talking and really formed a much closer bond and got really honest about everything. And it has brought us so much closer because there's no judgment. We're just really supportive of each other. And so from what I saw in my family is talking about it, hitting it head on, being honest and not throwing the person away is so important. And an opioid addiction-- we'll just talk about opioids-- opioids hijack the reward system in the brain so powerfully that you are not just being a bad actor, misbehaving, or just getting high. In my nephew's own words were, after six months or so, he never got high from heroin again. He was just running from withdrawal every four to six hours. And then withdrawal is a complete fight or flight state of mind where you think you literally believe you're gonna die. And if I put you in a state of absolute fear and terror, and you believe your life is imminently gonna end, at the core of your being deep in the neurochemical structure of your brain, what are you gonna do? "I'm gonna have more willpower and I'm not gonna take these opioids." No, you're gonna do whatever it takes to make that go away and we're wired like that. So the more I've started to understand the neurochemical aspect of opioid addiction, and this translates to other addictions, but I specify this cuz this is what we have clearance for with the FDA. You go, "well, how important it is to remove that giant scary fight or flight, deep in the lizard brain part of our body, that primordial fear, to get somebody on a road to recovery." It's huge. It is the most important way to get them out of addiction. And so it's been really cool learning about this and really seeing how important this is to the journey of recovery. Lindsey Dinneen: Absolutely. And is there any one story in particular-- I'm sure there are many-- but during these clinical trials, have certain stories emerged that are really particularly compelling to you as to how this device is making a difference in someone's life? Daniel Powell: Yeah, there's a bunch. We always share stories of patients and all on our company chat. And I think someone always says, "I'm not crying. You're crying." So, I think that should be our company motto. We're adapting this for newborn babies too, so you wanna get everybody choked up, just go down that path. But I have two. One was, just a gentleman who has PTSD-- and we're not on label for PTSD, but PTSD was one of our secondary outcomes-- but PTSD is a constant state of fight or flight, which is what we're neuro modulating in the brain. But, he said, "I slept for the first time last night. I've never felt this peaceful in 10 years." So that, that was one, but the other one was in our initial clinical trial and a young lady named Eliza had really fought addiction for years, had been in and out of rehab and came in, her dad made her go back in, I think she's 21, 22. And in her words, she was mad. She didn't wanna be there. She was gonna detox and then get the hell out of there and never come back like she was done. She didn't wanna get better. She just wanted to get through detox, which just meant she would've relapsed two days later after getting out. And about two, three days into the process to the five day process of her detoxing, she recognized she was clearheaded, feeling like her old self cuz she wasn't on any meds. She wasn't on meds to taper off the opioid. She was on our system and she made a life altering decision right there to continue therapy, which she vocally swore she wasn't gonna do. They put her in a 30 day program post detox. Then she went on and I've heard back from her and the family. A year later she went into a sober living facility and had reached over a year sober. And her video and her story's on our website and you can watch it and I dare you not to tear up at the end. So the facility called us during the clinical trial and said, "this girl wants to do a testimonial." And so we piled in the camera equipment and drove from Houston to Austin as fast as possible and found a little room in the rehab facility, got some lighting up and just shot it on the spot. So it's not produced, it's just raw, and you just see the way she's beaming at how happy she was where she was in her life. And that was just on day five or six, that's before she went into long-term recovery. And we get those stories all the time. It's really exciting. Lindsey Dinneen: That is amazing. The impact that makes on not just the individual who, of course, their life is dramatically changed as a result, but all of the people who love them. Oh my goodness. I am sure that it's extremely hard on the family and loved ones as well because they're watching somebody in a difficult place. And so, oh my gosh, just the ripple effects of what y'all do is really amazing. Daniel Powell: Well, thank you, it's funny you said that. I was talking to somebody else yesterday and he goes, "have you thought of the legacy you're leaving?" He goes, "you're creating a legacy. They think of the families they're affecting and then the children that's gonna pass onto." And it, it got real humbling, real quick. I'm just fighting the FDA today for a second gen product and making sure our third party logistics is shipping. Stop and pull back and remember that we have a great culture here at Spark. Everybody knows they're part of something really important and come to work with that passion to make a difference in people's lives. Lindsey Dinneen: Yeah, absolutely. Well, I know that you've had experience with other companies and then of course with your own, but is there any particular moment that stands out to you because it kind of clearly confirmed that the medtech industry was the right one for you? Daniel Powell: Yeah, for sure. When I was at St. Jude Medical doing spinal cord stim and I got to go on a field ride and then talk to, I remember this old man had spinal cord stim, and he was in a follow-up visit and I was getting to do a ride along with the sales rep. And the man said, " a year ago, I I couldn't even get out of the chair without assistance and today I climbed a ladder" cuz of the pain relief he had from spinal cord stim. And just hearing those stories and this person telling you "this product made a difference in my life." But it then got really profound for me when I went to deep brain stimulation. And so I had the privilege of being on the launch team for St. Jude's deep brain stimulation platform in Europe. And with deep brain stimulation, the patient is put under kind of twilight anesthesia, holes drilled in the head, wires put in the brain, but then you wake them back up and have them do motor tests cuz you're taking this little wire and you're pushing it into a 3D space. The brain's like a bowl of jello. So imagine you're pushing a wire into Jello shooting for 3D space that you can't see, the size of a pea. And so to make sure you're on target, you wake the patient up and have them like draw a circle or sign their name. And that whole experience when you're working with the physicians to actively use the product and being a subject matter expert during the surgeries in the early days. It was the most amazing thing to be in the brain surgery,. And then having the patient cry cuz they, their hands have been shaking so much, they haven't been able to sign their name in a decade and here they are able to sign their name while their brain's exposed and their skull's open. It's just, it was just such I, I look around, I'm like, "how did I get here? This is a amazing." So I have a special place in my heart for anything deep brain stimulation. That, that was truly just an amazing part of my career. Lindsey Dinneen: Oh my goodness. So now you've come from a business background and so has that really helped your entrepreneurial journey and is that something that you felt like it did help prepare you for this particular company or is this a lot of learning on the way as well? Daniel Powell: Yeah, no, that business background didn't do anything for me with the game store. So, clear, clearly, clearly, no. So what happened after the game stores and I went to work for St. Jude and then onto Cyberonics down in Houston, which is now LivaNova that does vagus nerve stim in the neck for epilepsy and depression is, I actually learned the business. We went through a warning letter, so I learned all about quality. We went through FDA submissions that I was part of the meetings and audits. And I spent the next 15 years actually learning a skillset in an industry versus meandering my way so that when the opportunity came to start my own company, I kind of looked around. I was like, "oh, I know what to do." And what it was is respecting everything besides the business portion. So respecting that a quality system's important and you need a quality manager. And respecting that you need IP and respecting the engineering process has to happen and it's takes longer and it's messy. You're respecting that the legal stuff needs to be made, respecting and appreciating all that goes into running a clinical trial. And I say all that because I've been part of a company where the CEO just yelled at everybody to "get it done," but didn't really know what it took to get it done. And so I think that's what prepared me more was understanding and respecting all the various parts of the business. I don't have to totally understand it, but I have to be aware of its level of difficulty and the talent it takes to execute it properly. And I think that's really served to be successful. The other opportunity that presented Spark uniquely is my two co-founders with me. Alejandro has his PhD in neuroengineering and he's our CTO and he is an absolute expert in that domain. And so we got the technicals covered by him. We got the business covered by me. And then Navid Khodaparast has his PhD in neurophysiology and is our chief science officer. And so when it comes to the clinical studies and the science and everything, while there's some overlap with him and Alejandro, he comprehensively covers the science. So we got engineering covered and patents, science and grants covered with Navid. And then the business side and sales and marketing covered with me. And it created a wonderful balance where we didn't have three scientists or three engineers, or three business guys stepping on each other, but three very complementary skill sets that we all brought to the table. And if somebody's starting a company, I would say " find partners that fill out other skill sets you're never gonna be able to master." Lindsey Dinneen: Yeah. That's great advice. Surround yourself with good people that are complementary in their abilities and their knowledge. How do you personally prioritize your continued growth and learning as a leader? Daniel Powell: Hmm, that's an interesting question. Ooh, I'll look back to the first time I was a manager and I've come a long ways. I, I think a couple things have affected that is there was a point in time where you realized that supporting your team and enabling their success versus controlling them. And I don't know where I've started seeing that. I remember specifically as a, a director at Cyberonics and we could get in front of the board room and I started reading books more on being a manager. There's something that tripped the realization that I needed to enhance that skillset. There's like a book, like the first 90 days or something like that when you're a new manager and you outline a plan, and so I, I embarked upon that. And I was moving down to Houston, joining this department. And I just really got real serious about not just meandering down and doing it, but really having a very specific plan. And so I started to educate myself more and more, read books on leadership and think about it. And I made this change from needing to be seen and get the kudos. And it just dawned on me: if the people working for me, if I just said" it was because of them," I got all the credit, but then they got all the credit too. And you had a loyal team and they felt appreciated. So you could see a manager, a director gets into the boardroom and gets to present and shows everybody what he did when reality is his team did it behind him as opposed to a director or VP or that they'd have an opportunity to present to upper management. And when they go, "well, that's really good," you say, "ah, that was John. I couldn't have done it without him. This was all his research." "Oh, that was, Jane. She pulled this together, amazing talent on my team." And once you flip over and start understanding that managing gets really easy. You start to be able to cultivate loyal teams. I had a manager tell me, he sent me an article. The article was, "Is Your Manager for You, for Themselves, or Against You?" And it said, "you know, managers look at their employees three ways." One is the majority of 'em are for themselves. Look, "I'll throw you under the bus if I have to to move my career forward. But otherwise I have no Ill intent towards you, but you know, this is about me." That's the majority of managers. On a rare occasion you get managers who are for you, they're like, "I want to make you succeed. I'm confident in where I am. If you move in front of me, it won't even hurt my feelings, but I'm invested in you." I had a manager at St. Jude like that, and he was fantastic and really was that example. On the rare occasion you get somebody who's against you and they want you to fail. I also got that manager at a later point in time. And in the article and the wisdom said, "you run, leave the company. There is no surviving that and it's toxic and I'll tear you down." So I try to really be for my people's success. And then I think moving into the CEO role and starting the company really put the pressure on me. And then life had changed from books to this thing called YouTube. I could watch and so I just gobbled up videos by Simon Sinek and real thought leaders on, on how to lead and all these great voices that are out there. And we really try to adopt those styles of management and those philosophies into Spark. We spent a lot of time talking about culture and how we were gonna build a really good company that, that was great to work at in the early days. Lindsey Dinneen: Yeah. That's great. And then that's great advice too in general for a leader or an aspiring leader. Appreciate your people, support your people, and it changes everything. As an employee, you feel appreciated and feel valued and feel like your contribution makes a difference, so, that's great advice. I like it. Well, on a lighter note, perhaps, imagine someone were to offer you a million dollars to teach a masterclass on anything you want, does not have to be in your industry. What would you choose to teach and why? Daniel Powell: I like mentoring. I would love to teach, end to end, how do you bring a medical device to market. And, I think what I've done over the last four years, personally, my personal growth everywhere from raising money and the management of all these different processes. I love sharing that. I love being a resource to other, younger entrepreneurs on this journey, on that kind of stuff. So it would still be in this industry, I think, and I think it would reflect what I've learned and experienced and then been successful doing over the last four years. Lindsey Dinneen: Excellent. Well, we definitely need a masterclass on that. That would be a great topic. Daniel Powell: But I don't have the discipline to put a curriculum together. I'm telling you now. The question hurt, cuz in my mind I was like, "I don't have energy for that." Lindsey Dinneen: That is fair, but also you are currently a little busy with your own company. So maybe this could be your retirement gig or something just for fun. Daniel Powell: I'm a procrastinator and I wing stuff and I wouldn't prepare ahead of time. I would just say, I would just wing it. Lindsey Dinneen: Ok. Ok. Daniel Powell: It's horrible to say. I know. Lindsey Dinneen: Okay. Well, we touched on legacy earlier, but I am curious, what is the one thing that you would wish to be remembered for after you leave this world? Daniel Powell: I really hope what we're doing here, just two things. I hope the people I work with have good lives and got to go to work and not felt like somebody was against them. You see you're in these companies and the layoffs come and people get treated like numbers and we have had to have a layoff and there were people who were like, "this is not working for the business." But we try to be as humane and caring as possible when we're making tough decisions. So I'd like for the people who work for Spark, I hope this is an enriching part of their life, and that it allowed them to have a better family life. I mean, I just remember the stress of working for a company that's going through layoff after layoff, and you see bad managers treating people poorly and you sometimes get trapped there and you got nowhere to go. So I hope on one note for internally that I've made everybody who's part of this journey, their life better. And then I hope that we've really are gonna put some products into the world that, that had a legacy effect that saved families and brought 'em together. It's cool getting to work in medtech, right? We're not just making a widget, but this widget has real effects on lives. I'm lucky I get to work in this industry. It's really cool. Lindsey Dinneen: Yeah, absolutely agree. Yeah. Well, and my final question is what is one thing that makes you smile every time you see or think about it? Daniel Powell: I think our work in the neonatal space is just the most rewarding thing in the world. So these newborn babies born physically dependent on opioids. And that gets me up early every single day and keeps me motivated. We're not on market with the baby product yet, but we're in our big clinical trial and it's just cool. I always smile when I just even think the serendipity of how this happened. So I was on a flight to San Francisco to go to the Neurotech Reports conference, and I was putting my first investor PowerPoint together. And so I've got internet connection and I'm looking up, " how many people die of opioids and how many Americans are addicted" and putting all the numbers together. And I come across neonatal opioid withdrawal syndrome and I start to read about it and how these babies are born and they just go through a horrible, excruciating first month of life. And, They had this like unnatural scream or cry and they don't feed, and I was like," oh my gosh. We have to do something about this." And so I sent an email to Navid and Alejandro and I'm like, "look at this article. We are gonna do this too, even if we don't make money." And by the time I landed, they both had replied, "we're all in." Like on that day we started the neonatal program and started researching. The next day I went to the first session and the first panel was New Science Discoveries. And about the second presenter was Dr. Bashar Badran out of MUSC. And he was presenting his auricular vagus nerve stimulation results on newborn babies for stroke recovery for feeding. So in front of me was the only person in the world who had ever stimulated a baby's ear and had brand new breaking results. And I mean, I was " what are the chances 24 hours after we see this?" So he, he finished speech and got off the stage and I ran up like a crazy man and I'm like, "we're gonna work together" and he was like, like, "wow." I was just, it was just I and I-- Lindsey Dinneen: Wow. Daniel Powell: My, my wife said several times "the universe conspires to make us successful." I think what we're doing is good and is noble. And things like that, I mean, and so it took him over two or three years to get his IRB approval to run his first baby study. We piggybacked on their IRB approval and had approval in 60 days. So I mean like probably shaved two years off getting this product to market. It's really amazing. So that makes all, that makes me smile every time. Lindsey Dinneen: Oh yeah. And that's a fantastic story. Oh my goodness. Thank you for sharing that. Well, thank you, Daniel, so, so very much for joining me today. Thank you for all of your insights and your stories. I'm so inspired by what your company is doing, how it's helping-- just again, the ripple effects. I keep thinking about that and that's just that's really amazing. So, so thank you for what you all are doing to help change lives. And we are honored to be making a donation on your behalf as a thank you for your time today to Threads of Love, which through the effort and support of many participants and chapters across the country, provides clothing, blankets, and other handmade articles for tiny, premature and sick infants. And I just think, Daniel, that works so well with exactly what you were just talking about and your heart for others. So thank you for choosing that organization to support. Thank you again for your time. I just wish you continued success as you work to change lives for a better world. Daniel Powell: Thank you so much. I appreciate the chance to tell the story. Lindsey Dinneen: Yeah, absolutely. And thank you also to our listeners for tuning in and if you are feeling as inspired as I am right now, I would love if you would share this episode with a colleague or two and we will catch you next time.  The Leading Difference podcast is brought to you by Velentium. Velentium is a contract design and manufacturing firm specializing in the development, production and post-market support of diagnostic and therapeutic active medical devices, including implantables and wearables for neuromodulation and other class three indications. Velentium's core competencies include electrical design, mechanical design, embedded software, mobile apps, contract manufacturing, embedded cybersecurity, OT cybersecurity, systems engineering, human factors and usability, and automated test systems. Velentium works with clients worldwide from startups seeking seed funding to established Fortune 100 companies. Visit velentium.com to explore your next step in medical device development.

In this special extra episode of Medtech Insight's podcast series on cardiovascular technology, editor Reed Miller talked to Vish Charan, the divisional vice president of product development in Abbott's cardiac rhythm management division. [C#4052:Abbott] aspires to be a leader in development of "future-ready" cardiac rhythm management (CRM) devices that do not need to be frequently replaced or explanted. Late last year, Medtech Insight talked to Leonard Ganz, Abbott's CRM business as its divisional vice president of medical affairs and chief medical officer, to talk about the company's development of leadless CRM devices, including Aveir VR, the only leadless pacemaker with unique mapping capabilities that can be easily retrieved as the patient's need for new therapies change. ([A#MT145700]) To get the engineer's perspective on how Abbott is trying to keep up with [C#72:Boston Scientific] and [C#252:Medtronic] in this space, editor Reed Miller recently talked to Vish Charan, the vice president of product development in Abbott's CRM division. Charan is all too familiar with the challenges of managing traditional cardiac leads, since he started his career as an engineer working on cardiac leads at [C#1191:St. Jude Medical]; he joined Abbott as an operations leader when Abbott acquired St. Jude about six years ago. He also talked about his role with the company, the future of transvenous devices, and the potential to reach more patients earlier in the progression of arrhythmia to save lives and costs. Use the player below to hear the whole interview. Further Reading For more information on leadless CRM technology discussed in this interview, check out these articles from Medtech Insight. Minute Insight: Abbott Rolls Out Navitor Next-Gen TAVR System To Catch Up To Medtronic And Edwards Medtronic's Extravascular ICD Hits Targets In Trial; Will Soon Compete With Boston Scientific's S-ICD Exec Chat: Abbott Bets On Modular And Leadless Devices To Be The Future Of Cardiac Rhythm Management Cardio Conversations: Abbott's Electrophysiology CMO Christopher Piorkowski On Cardiac Mapping, PFA, VT And More Minute Insight: Abbott's Aveir VR To Take On Medtronic's Micra In US Leadless Pacemaker Market Cardiovascular Catch-Up: Abbott Launches Trial Of Dual-Chamber Leadless Pacer; Cardialen Studies Low-Energy Arrhythmia Treatment; And More Boston Scientific Advances First ‘Modular' Cardiac Rhythm Management System Further Listening Our other podcasts are available on Apple Podcasts, Google Podcasts, SoundCloud and TuneIn - also now on Spotify Podcasts - and via smart speakers if one of these platforms has been set up as your default podcast provider.

In a recent study done among manufacturing leaders, 88% of them listed "Operational Resilience" as a key emphasis for the near future. 65% of the leaders stated that "Improving Operational Efficiency" was a key priority as well. When it comes to these two concerns, digital transformation is a vital part of ensuring that each department and all end users are empowered with the right tools and data to perform their duties most effectively and most accurately. In this episode, we interview Howard Hohnadel with MCA Connect to highlight the digital transformation challenges and successes manufacturing companies face today and how D365 can help. Episode Topics: What are the top digital transformation obstacles customers face in the Manufacturing Industry? How are customers using D365 in the Manufacturing Industry? Where are customers finding the most success with D365 within the Manufacturing Industry? Please share a customer success story from the Manufacturing Industry. Useful resources: Dynamics 365 for Manufacturing Dynamics 365 for Supply Chain Management MCA Connect Website As MCA Connect's VP of Solution Development and 20+ years of management consulting experience, Howard helps companies simplify the complex by rethinking supply chain strategies and processes. He collaborates closely with clients' supply chain operations teams, solution partners, and MCA Connect's product development team to drive innovation and value through strategic ERP/CRM implementations. Over the course of his career, Howard has worked with a diverse range of companies, including self-funded startups and major international enterprises like Toyota, Dell, Panasonic, Wells Fargo, and St. Jude Medical. MCA Connect is an experienced, award-winning partner that helps manufacturers uncover possibilities and overcome challenges through strategy, implementation, intelligence, and support services. With more than 20 years of deep manufacturing expertise, they've guided manufacturers through some of the most complex scenarios in the most tumultuous times. As the Global Partner of the Year finalist this year for Dynamics 365 Supply Chain Management, we're excited to have them on the podcast today to talk manufacturing and supply chain! Connect with Howard Hohnadel here – Howard Hohnadel | LinkedIn We'd love to hear from you: Don't hesitate to reach out with any questions, comments, suggestions, or feedback! We'd love to hear from you. Send your hosts an email at digestibledynamics@microsoft.com Discover and follow other Microsoft podcasts at microsoft.com/podcasts Hosted on Acast. See acast.com/privacy for more information.

On this episode of SPOT radio, Charlie Webb CPPL speaks with Brian Nissen, Jennifer Benolken, and Amy Stewart from the IOPP's Medical Device Packaging Technical Committee (MDPTC) about the upcoming "Fundamentals of Medical Device Packaging" course. Listen in and learn about this exciting new event. Guest bio's:Brian Nissen, CPP received his Bachelor of Science in Mechanical Engineering from the University of Minnesota. He has been with QTS for twelve years and currently holds the position of Project Engineering Manager. Brian has over twenty years of experience in the medical device industry and has previously held positions at Medtronic, St. Jude Medical, American Medical Systems, and Lifecore Biomedical.  Brian holds current certifications as a Certified Packaging Professional (CPP) and Six-Sigma Green Belt (CSSGB) Certified Lean Practitioner and has previously held certifications as a Certified Quality Engineer (ASQ-CQE) and Certified Quality Auditor (ASQ-CQA) Amy Stewart, Product Development Manager - Printpack Medical, has 25 years of experience in the flexible packaging industry in operations and technical roles for healthcare and various other markets including food, health and beauty and industrial.  Amy is committed to impacting patient safety through her work and with industry organizations in medical device packaging.  She serves as program leader for the IoPP Medical Device Packaging Technical Committee Fundamentals of Medical Device Packaging course and formerly served as Chairperson of MDPTC, named 2020 Technical Committee of the Year.  Also, Amy serves on the FPA Sterilization Packaging Manufacturers Council (SPMC), which established the annual Sterile Packaging Day and promotes patient safety awareness and celebrates the supply chain organizations dedicated to patient safety.  Additionally, Amy supports leadership programs as a mentor within her organization and specifically, women's leadership in the Greater Atlanta business community.Jen Benolken, CPPL, is a Medical Device and Regulatory Package Engineering Specialist with DuPont Tyvek® Medical Packaging. Jennifer works with DuPont Tyvek®'s medical and pharmaceutical downstream customers. For the past 30 years, Jennifer has played an active role in the medical device packaging community through industry organizations, speaking engagements and by holding a variety of different roles in the value chain, including packaging, labeling and sterilization. Currently Co-Chair and DuPont's Primary Member for AAMI's ST/WG7, Packaging Working Group, the US's mirror group to ISO TC198/WG7, Jen also represents the U.S. as a delegate to the ISO Packaging Working Group. Additionally, Jen is the Sub-Committee Chairperson for ASTM F02.50, Package Design and Development. Jen has been a long-term member of the Institute of Packaging Professionals, currently serving on the National Board of Directors. She also is Chairperson for IoPP's Medical Device Packaging Technical Committee.Registration Link: https://www.iopp.org/i4a/pages/index.cfm?pageid=4833LinkedIn page: https://www.linkedin.com/company/iopp-mdptc e-mail: jennifer.a.benolken@dupont.com 

This week we interview Keith Grossman. Keith was named CEO and President of Nevro in March of 2019. Keith has over 30 years of experience in the medical device field. He served most recently, and for the second time, as the President, Chief Executive Officer, and director of Thoratec Corporation, leading up to its 2015 sale to St. Jude Medical. He currently serves as Vice Chairman of Alcon, Inc., and Chairman of Outset Medical, Inc. and previously served as a member of the Board of directors of Intuitive Surgical, Inc., Kyphon, Inc., ViewRay, Inc., Zeltiq, Inc, and a number of privately held medical device companies.

Manny Villafana is responsible for some of the most important breakthroughs in cardiovascular health care in the last five decades starting with Cardiac Pacemakers Inc. (CPI), the world's first lithium-powered pacemaker and St. Jude Medical, which introduced the heart valve that became the industry standard and was sold to Abbott Laboratories in 2016 for $25 billion. He's now working on his eighth startup, Medical 21, which is developing an artificial artery for bypass surgery. Human clinical trials could start in the next six months. His career history reads like a playbook on innovation. “If you don't take risks, nothing's going to happen,” says Villafana, who is 81 and shows no interest in slowing down. “I go after things that people say can't be done. That's one of the greatest pleasures in life. Just go the opposite direction.” He charts some key career highs and lows, from being fired by Medtronic and then sued by the company that eventually gave him free access to its patents and bought his second valve company, ATS Medical, for $370 million. Villafana has taken seven companies public in his career, but still, he says, raising money is a grind, and over the course of his career, investors have become even more adverse to risk, he says. “The work is hard in any startup, but with a medical tech company, you have to be Superman to withstand the regulatory process,” he says. “Make sure you've identified a need.” Back to the Classroom Innovation at its core is knowing there's a better way, coupled with the courage to pursue it, even in the face of adversity, says Kjrk Reyerson, executive fellow and adjunct professor of Healthcare Innovation at the University of St. Thomas Opus College of Business. “There might not always be a playbook,” Ryerson says. “What is your passion? What fuels you?” Passion is essential to moving a new idea. “What you're representing is change,” Ryerson says. “Most human beings doing like change. How do we incentivize the way we think about change as something to be celebrated?”

We embark into the Labyrinth with American business leader Dan Starks, who was at the helm of executive leadership for 5 enterprise companies. Currently Dan serves as an Executive Board Member of a Fortune 100 Company, Abbott Laboratories, one of the world's largest medical device and healthcare companies. He was also the CEO for 12 years at a Fortune 500 Company for St. Jude Medical. Dan discusses his principles of leadership for developing a culture of thriving teams by empowering their state of mind and implementing measurable goals. Dan shares how to navigate the corporate waters as a new CEO, the mistakes most new Chief Executives make and how to become an impactful leader holding Executive Office. Dan shares his obstacles and triumphs along the road of life, his unconventional journey, how to find happiness within and his conversations with his Holiness the Dalai Lama. Dan is also the founder of the world renowned National Museum of Military Vehicles in Dubois, Wyoming. This is one wild interview that will inspire your thoughts, principles and perspectives of leadership success in your career and in life. Are you ready to Ignite Your Light? National Museum of Military Vehicles Official Website:  https://nmmv.org/ (nmmv.org) National Museum of Military Vehicles Official Instagram: nmmv_wy Dan Starks' Book Recommendation: Ethics by Aristotle 

Assent Compliance's Travis Miller and Jared Connors join us as they discuss their work in conflict minerals supply chains, how ESG compliance plays a role, what companies should do to interpret data and increase efficiency and recovery, and the future of risk management.  ▶️ ESG Supply Chain Compliance with Travis Miller and Jared Connors: Key points discussed in the episode: ✔️ Companies are starting to realize the significance of making a commitment to ESG through responsible sourcing. ✔️ Outsourcing usually occurs in the most regulated, most dangerous, and least profitable businesses.  ✔️ Business continuity planning is crucial in risk management, more flexible disaster response, and efficient operations. Aside from environmental and social, risk is also a financial concern. ✔️ The most important letter of ESG is P – product, people, and policies. Middle-aged workers are the most vulnerable and highly targeted in inhumane business practices and violations. ✔️ Dig deeper into organizations and understand their commitments to mitigate and prepare for risk.  ✔️ Non-financial risks are pressuring investor disclosures. ✔️ ESG is reorienting the global market and the world. Large-scale environmental and social scandals ruin reputation and business. ✔️ Educating the supply chain contributes to overall company efficiency and risk management. ✔️ Compliance toolkits should be utilized even outside the company. The legal space has become the ideal practice ground for compliance. ✔️ Companies should be proactive in detecting supply chain issues internally. ✔️ Translate technical speak to an executive language to gain interest from the C-level suite. ✔️ Assess supply chain maturity. ✔️Companies are now compelled to make a change due to their global influence. Consumers' cries for environmental and social accountability are now heard – all thanks to social media. Jared Connors is a senior subject matter expert on Corporate Social Responsibility at Assent Compliance, the worlds' leader in supply chain data management. His expertise involves achieving ESG goals by understanding and mitigating potential supply chain risk, the transition from CSR to ESG, how companies can take a holistic approach to ESG, and ESG-related regulations, such as those pertaining to human trafficking and slavery, conflict minerals, and anti-bribery, anti-corruption. Travis Miller is an international trade and compliance attorney who specializes in ITAR/EAR/sanctions, global anti-corruption and anti-slavery, codes of conduct, environmental health and safety, product stewardship, and corporate social responsibility. He manages Assent's worldwide legal activities, advises the Board of Directors on legal matters, and oversees corporate compliance, governance initiatives, and other commercial transactions. Before coming to Assent, he served in various high-level counsel positions with companies such as Microchip Technology, Foresite Group, and St. Jude Medical. ---------------------------------------------------------------------------- Do you have a podcast (or do you want to)? Join the only network dedicated to compliance, risk management, and business ethics, the Compliance Podcast Network. For more information, contact Tom Fox at tfox@tfoxlaw.com.

Dzisiejszy gość Jarosława Wydry przez ostatnie 20 lat kierował przedsięwzięciami z branży medycznej na prawie wszystkich kontynentach. Marcin Gołębicki jest członkiem rady nazdzorczej w Medinice i inwestorem w branży. Czy trudno pogodzić cel biznesowy z celem branży medycznej jakim jest niesienie pomocy cierpiącym? Co zrobić w sytuacji sprzecznych dążeń akcjonariuszy i klientów? Czy jest tu przestrzeń do kompromisu? Czy gościowi zdarzyło się zrezygnować z jakiegoś zadania z powodu niezgodności jego przekonań z linią firmy? Jakie ma marzenia? Marcin Gołębicki to ekspert branży medycznej, w szczególności w dziedzinie związanej z ochroną zdrowia i sektorem MedTech. Piastował najwyższe stanowiska kierownicze w gigantach branży MedTech tj. Johnson & Johnson, Boston Scientific, St. Jude Medical, Abbot czy Philips. Ponadto był także Prezesem oraz Członkiem Rady Nadzorczej spółki Medicalgorithmics S.A. Obecnie Członek Rady Nadzorczej Medinice S.A. Cykl, w którym oddajemy głos ludziom odnoszącym sukcesy w biznesie, prowadzi Jarosław Wydra. Pyta o ich codzienność, biznes, pracę, dylematy, wybory i historie. Audycje takie jak ta powstają w Radiu Warszawa tylko dzięki wsparciu finansowemu Przyjaciół i Słuchaczy. Również Ciebie zapraszamy do tego fantastycznego grona! Kliknij i wspieraj: https://www.bank-sluchaczy.pl/ Możesz też słuchać nas na 106,2 FM w Warszawie i okolicach, lub on-line na https://radiowarszawa.com.pl/radio-warszawa-online-sluchaj-live/ Wybór podobnych audycji tematycznych znajdziesz rownież na https://www.youtube.com/channel/UCobZ59BIAH3CSgD7baR9Qig https://radiowarszawa.com.pl/audycje/ Spotify https://open.spotify.com/show/5Gcq7dtwpQIcv3ub87fD7d https://open.spotify.com/show/1e3bbTwl5B3aSfbTR2MfW8 Chcesz włączyć się w naszą społeczność? https://www.facebook.com/radiowarszawa https://www.instagram.com/radio_warszawa/ https://twitter.com/radiowarszawa

Inspiration often comes from life-changing experiences, and today’s guest Kaile Zagger is no exception. Her experience witnessing her mother experience ovarian cancer at a young age inspired her to become part of a health organization focused on providing treatment and awareness for women’s cancer issues. Listen in as we discuss how Kaile rallies support and visualization of company goals, leads her team to focus on outcomes, and stays personally motivated by past and present experiences. Kaile Zagger is the Chief Operating Officer of Aspira Women’s Health, combining commercial sales and operations into one role. She oversees the entire provider and patient experience, from acquisition to billing. Her goal is to create a platform that scales the business and retains a customer experience that is second to none. Kaile is an accomplished industry executive with 20+ years in healthcare. Prior to joining Aspira Women's Health, Kaile served at various Fortune 500 healthcare companies, including St. Jude Medical, Intuitive Surgical, and General Electric Healthcare. Kaile joined Aspira because of a deep passion for the company’s mission and vision. She has personally experienced the devastating nature of late-stage ovarian cancer, beginning with her mother’s diagnosis at the young age of 40 and her passing from this horrific disease at 46 in 1999. Because of this, she is fiercely committed to the prevention, early detection, and mitigation of late-stage diagnosis. Kaile and Elena Ratner, M.D., co-founded the MAT Organization, a non-profit established to drive early detection for ovarian cancer and to eradicate late-stage diagnosis through exhaustive education in the provider community, the first approach of this kind. Kaile holds a bachelor's degree from the University of Connecticut. You can learn more about Aspira here: https://aspirawh.com/ Do you have what it takes to have it all? Book 15-minute clarity call to see how you can create the roadmap to your own Peaceful Achievement success story.See omnystudio.com/listener for privacy information.

Kaile joins Aspira as the Chief Operating Officer, combining commercial sales and operations into one role. She oversees the entire provider and patient experience, from acquisition to billing. Her goal is to create a platform that scales the business and retains a customer experience that is second to none. Kaile is an accomplished industry executive with 20+ years in healthcare.Prior to joining Aspira Women's Health, Kaile served at various Fortune 500 healthcare companies, including St. Jude Medical, Intuitive Surgical, and General Electric Healthcare. Kaile joined Aspira because of a deep passion for the company's mission and vision. She has personally experienced the devastating nature of late-stage ovarian cancer, beginning with her mother's diagnosis at the young age of 40 and her passing from this horrific disease at 46 in 1999. Because of this, she is fiercely committed to the prevention, early detection, and mitigation of late-stage diagnosis.Kaile and Elena Ratner, M.D., co-founded the MAT Organization, a non-profit established to drive early detection for ovarian cancer and to eradicate late-stage diagnosis through exhaustive education in the provider community, the first approach of this kind. Kaile holds a bachelor's degree from the University of Connecticut.Connect with Kaile Website Follow The Story Box on Social Media► INSTAGRAM ► TWITTER ► FACEBOOK ► WEBSITE SUBSCRIBE FOR MORE! ► Apple Podcast ► Spotify WATCH HERE:► YouTube If you enjoyed this episode please subscribe to YouTube & Apple Podcasts, and leave a 5-star positive rating and review over on Apple Podcasts. Share it around with your friends and family.Support The Show Here:Support this show http://supporter.acast.com/thestorybox. See acast.com/privacy for privacy and opt-out information.

What is leadership, anyway? Such a simple question, and yet it continues to vex popular consultants and laypeople alike.  Leadership is a process of social influence, which maximizes the efforts of others, towards the achievement of a goal.   In this episode of DeviceAlliance's Medtech Radio, we speak with the President of Bioplatte, Thomas Hopson.  Thomas Hopson is an accomplished business executive with over 30 years of experience in the medical device industry. Thomas has provided leadership to multi-million-dollar business enterprises in Europe, Asia, and the United States, and he has successfully transformed multiple struggling organizations into healthy and thriving businesses. He joined Bioplate as President in 2018, bringing with him an extensive background in sales, business development, organizational learning, and product commercialization. Before joining Bioplate, Thomas served as the Director, Global Talent Management & Learning at Edwards Life Sciences. Prior to Edwards, Thomas held various leadership positions at St. Jude Medical.   Join us as we discuss his life's journey into leadership, his most valuables mistakes, keeping teams motivated in times of crisis, how to handle making unpopular decisions, and key trends in key trends in the global craniofacial fixation market.

In her early school days, Jamie wanted to be a doctor.  When she headed off to her first classes at DePaul University in Chicago, she was dismayed by just how long science lab classes were, so her childhood career choice was dashed shortly thereafter. She decided to stick to the core classes until she was forced at the end of her sophomore year to declare a major.  She decided to go with business. While taking a variety of business related classes her last two undergrad years, she encountered business law. Finally, she had found a discipline that truly interested her.   Since De Paul has a community service component to its curriculum, Jamie chose to mentor group home boys who were wards of the state. She enjoyed this work and thought as she went off to law school, she would explore child advocacy law.  She enrolled at Hamline University in St. Paul, Minnesota, which offered a concentration of courses on children and the law.   Midway through law school it occurred to her that she was amassing a lot of student loan debt.  She began to think about how she would eventually repay it and she came upon an idea she thought would help her. It happened that Hamline offered a dual degree program with the nearby University of St. Thomas where she could earn an MBA to accompany her JD. When she finished these two degrees, she felt she would be better prepared to land a good first position and relieve some of her debt.   Jamie's first job out of law school was as a business litigator.  She did this for 2 years and got her feet wet, and as she did, she was able to define her career direction further.  She felt she wanted to be an integral part of building a business and creating new systems.  She left this initial job then and hired on at US Bank where she might find more opportunity to grow.   At U.S. Bank she was brought in to support the IT department. In that role she did everything from litigation to software licensing to contract negotiations.  Each of these areas offered her more experience to help her continue to define and develop her career path.  When she had finished at US Bank, she felt better prepared to step up to the role of an in-house counsel.   Jamie's next move was to Kroll Ontrack as a contract negotiator and then associate legal counsel.  Besides contract negotiations she did compliance and document discovery. After a 3 year stint, she moved on as counsel at St. Jude Medical where she continued to do contract law.   In 2017, she was hired as the first in-house attorney at Gitlab.This was her first remote job.  During her time there, the company enjoyed tremendous growth. They went from 150 to 1200 employees. Jamie built the legal team from just herself to 7 others.  It was exciting and a lot of work, she tells us.  She felt an integral part of the team, and this was the type of work she had been building towards.   When the pandemic hit, Jamie took a sabbatical.  During her time off, an opportunity came to join Mattermost, an open source collaboration platform for developers.  The entire company works remotely.  Jamie took the position and has found remote work affords her the flexibility she needs. With four children and her academic responsibilities at Georgetown University where she is a candidate for an Executive LLM in Securities and Financial Regulations, flexibility is essential. As the first in-house attorney at Mattermost, Jamie is busy setting up the requisite legal systems for the company. Her responsibilities often include reworking contracts, document discovery and compliance issues too.   Jamie discusses with Amy some of the work she does to promote rising people in technology fields and other areas. For example, she works as a mentor with TechStars, an incubator program with United Health Care. Recently she's developed a list serve for attorneys who work for remote businesses, many being technology startups. (You can find the link below). The list has grown to 60 or 70 lawyers so far.   So at this stage of her ever-evolving career, she wears many hats.  She's happy with her current work and lifestyle and shares some advice about what she's learned as an attorney at several startups.  She says networking is vital.  She tells the listener exactly how she networked to make her way into the startup world. She has pivoted successfully because she has acquired an impressive array of transferable skills, learning and adapting as she moves forward.  During a time of rapidly changing technology, her ability to stay current makes her highly valuable to every organization she chooses to be involved with.   Takeaways:     Network and develop relationships of trust Keep learning Lawyers working with startups experience a unique set of challenge Not everyone follows a career path plotted early on   Links: linkedin.com/in/jamiehurewitz www.allremotelegal.com

Schön, dass du wieder eingeschaltet hast bei unserem Podcast Finanzen.Parkett. Wir möchten dir heute den Konzern Abbott Laboratories vorstellen. Das Kerngeschäft von Abbott Laboratories liegt hierbei in der Erforschung, Entwicklung und Herstellung verschiedener Arzneimittel aus Humanmedizin und Veterinärmedizin (Tiermedizin) sowie in den Bereichen Labordiagnostik und auch in der klinischen Ernährung. Disclaimer: Bei der Vorstellung handelt es sich um keine Anlageberatung, sondern lediglich um unsere eigene Meinung. Kurze Vorstellung: - im Jahre 1888 durch den Arzt und Apothekenbesitzer Wallace Calvin Abbott - im Jahr 1985 hat das Unternehmen den ersten diagnostischen HIV, in Form eines Blut Screening Verfahren, Test auf den Markt gebracht - 2017 Übernahme von St. Jude Medical für 25 Mrd. USD (das medizinische Geräte für Krankheiten des Herzens und des Nervensystems herstellt: Herzschrittmacher, implantierbare Defibrillatoren, Neurostimulatoren und Herzklappen) Mitarbeiter: über 107.000 weltweit Aktienkurs vom 09.7.2020: 81,36€ Marktkapitalisierung: 160 Mrd. USD Produkte von Abbott: Medikamente, Diabetes Screener, Nahrungsergänzungsmittel, Kardiologie Produkte, Neurostimulation, Diagnosegeräte und Test Pro und Contra: + starkes Gewinn und Umsatzwachstum + das Unternehmen besteht schon sehr lange am Markt und hat 2 Weltkriege überlebt + die Dividende wurden in den letzten 45 Jahren immer weiter gesteigert + in den letzten 5 Jahren würde die Dividende im Durchschnitt um über 8% p. a. angehoben + Spezialisierung auf Glucosemessung, Stents, Systeme für die Herzunterstützung und daher Weltmarktführer - die Umsätze im Pharmaziebereich sind eher als stagnierend anzusehen (kaum Umsatzwachstum) - Zulassung von medizinischen Produkten/ Geräten sind sehr kostenintensiv - hohe regulatorische Anforderungen vor allem durch die FDA (Food and Drug Administration) - hoher Dokumentations- und Archivierungsaufwand im Pharma und Medizinbereich - Patente sind zeitlich begrenzt (nach Recherche max. 20 Jahre) Falls du weiter Informationen möchtest: Jannik: Finanzenfuchs -- https://www.instagram.com/finanzenfuchs/ Gerrit: Parkett.Hirsch -- https://www.instagram.com/parkett.hirsch/ Unser Blog: https://www.finanzenparkett.de Neues Produkt: Finanzen-Check (https://forms.gle/sTFFkRwZ3S7ZZkc27) Danke für deine Aufmerksamkeit und bis zum nächsten Mal, dein Team von Finanzen.Parkett. Empfehlungen: Kryptowährungen handeln über die Bison-App (https://join.bisonapp.com/wcwh7m) (*) (investiere 50€ und erhalte 10€ extra einmalig) Investiere noch heute in Privatkredite (*keine Anlageberatung/ hohes Risiko): Mintos: https://www.mintos.com/de/l/ref/IL0XQS Bondora: https://bondora.com/ref/jannikh Anmerkung: Werbe-/ Affiliate Links: Die mit (*) gekennzeichneten Links sind Affilatelinks. --- Send in a voice message: https://anchor.fm/finanzen-parkett/message

Frank Fischer, Chairman of the Board, Neuropace Frank Fischer has more than 40 years of senior management experience in the medical device industry. He co-founded NeuroPace in Dec 1997, led the company as its President and Chief Executive Officer from January 2000 thru July 2019, served on its Board of Directors since inception and is currently Chairman of the Board. Prior to joining NeuroPace, Mr. Fischer was President and Chief Executive Officer of Heartport, Inc., a cardiac surgery company, from May 1998 until September 1999 and served on Heartport's Board of Directors. Previously, Mr. Fischer was President and Chief Executive Officer and a director of Ventritex, Inc., a company that pioneered implantable cardiac defibrillators, from July 1987 until the sale of the company to St. Jude Medical, Inc. in 1997. Before joining Ventritex, he held various management positions at Cordis Corporation from 1977 to 1987 in the cardiac and neurosurgical device areas, serving most recently as President of the Implantable Products Division. Currently he is a member of the Board of Directors of Nevro, Inc., the Board of Trustees of both Rensselaer Polytechnic Institute and Babson College as well as the Board of Directors of the Epilepsy Foundation of America. Mr. Fischer holds B.S.M.E. and M.S. in Management degrees from Rensselaer Polytechnic Institute.

Vanja Hoeben, MMO is Head of Commercial Operations BeNeLux at Aspen Pharma. Toen ik Vanja sprak voor dit interview was hij salesmanager neuromodulatie bij St. Jude Medical. Dit medisch-technologische bedrijf ontwikkelt en produceert medische instrumenten. Ook voor neuromodulatie, een soort draadje dat wordt aangebracht in de ruggenwervel van iemand met chronische pijn. Door het draadje gaat een klein stroompje, dat als het ware de pijn maskeert. Vanja is iemand met duidelijk veel ervaring. “Ja, veel ervaring en de nodige wijsheid, maar ik leer elke dag. En ik denk ook dat je daar als manager ook echt voor moet openstaan. Zorg ook dat je goed kijkt naar wat mensen doen en goed luistert naar wat ze zeggen. Dan kom je al een heel eind.” Een podcastaflevering vol mooie tips en inspirerende verhalen. Elke dag leren, adviseert Vanja: wat heb jij vandaag geleerd? #podcast #management #neuromodulatie #stjudemedical #chronischepijn #Aspen

2017-01-31 Special EnglishThis is Special English. I&`&m Ryan Price in Beijing. Here is the news.China will quadruple its new energy vehicle annual output to 2 million by 2020. A government plan released by the Industry and Information Technology noted that by 2025, at least one in every five cars sold in China will be a new energy model.Last year, China produced 517,000 new energy vehicles. The country has been the world&`&s top seller of such environment-friendly cars since 2015. The cumulative sale has exceeded 1 million.New energy vehicles include battery electric cars, plug-in hybrids, and fuel-cell cars.Last year, three top Chinese electric carmakers sold their models in more than 30 countries and regions around the world.The government will continue to improve policies, boost research and development, invest in charging infrastructure construction, and promote international cooperation to help the sector grow.In terms of charging infrastructure, China built 100,000 public charging poles in 2016, ten times the figure in 2015. A comprehensive charging grid has taken shape in big cities including Beijing, Shanghai, and Shenzhen.China witnessed a boom of electric vehicle investment in the past few years, largely thanks to government&`&s incentives.This is Special English.An oil-electricity hybrid locomotive, the most powerful of its kind, has started in an experiment in extreme cold weather in northeast China.The experiment was conducted in the northern part of the Inner Mongolia Autonomous Region, when the local temperature was minus 40 degrees Celsius.Despite the cold, the temperature in the cab was 25 degrees Celsius. The batteries were 12 degrees Celsius, suitable for operation.The manufacturer says the experiment marked the end of a series of experiments for the hybrid locomotive.In earlier experiments, the locomotive was run under a temperature of minus 30 degrees Celsius in northeast China.Last year, it operated in high temperatures in northwest China&`&s Xinjiang Uygur Autonomous Region.Hybrid locomotives are environment friendly, energy-saving and less noisy. The successful experiments mean that the world&`&s largest-power hybrid locomotive can run in all weather conditions.You&`&re listening to Special English. I&`&m Ryan Price in Beijing. Facebook is launching a journalism project aimed at strengthening its ties with media organizations. The move aims to expand their audiences, come up with new products and generally promote trusted news in today&`&s "post-truth" era.The project is in its early stages and as such, is light on its specifics. But the company envisions Facebook engineers working with news organizations to create new ways of telling stories and novel advertising or subscription models, right from the early stages of development. The company also wants to help promote "news literacy" and support local news.Dave Merrell, lead product manager at The Washington Post, which is among the news organizations working with Facebook, said it is very early in the process but certainly something they are really excited about. He said he worked with Facebook on numerous products over the years, but often were not involved in the product development stage.With "Instant Articles" launched in 2015, Facebook hosts and displays news items directly instead of pointing users to news websites. Such instant stories load faster on Facebook than those on outside links, and Facebook gives participating publishers a cut of the advertising revenue from Instant Articles.This is Special English.The U.S. Homeland Security Department has warned about an unusual cybersecurity flaw for one manufacturer&`&s implantable heart device where it is said it could allow hackers to remotely take control of a person&`&s defibrillator or pacemaker.Information on the security flaw was identified by researchers at MedSec Holdings in reports months ago. It was only formally made public after the manufacturer, St. Jude Medical, made a software repair available earlier this month. MedSec is a cybersecurity research company that focuses on the health-care industry.The government advisory said security patches will be rolled out automatically over months to patients with a device transmitter at home, as long as it is plugged in and connected to the company&`&s network. These transmitters will send heart device data back to medical professionals.You&`&re listening to Special English. I&`&m Ryan Price in Beijing. The first self-sufficient boat powered by only emission-free energy will start a six-year trip around the world in the spring.Energy Observer is a former multi-hull race boat converted into a green vessel equipped with solar panels, wind turbines and a hydrogen fuel cell system. This means that it will be powered by the wind, the sun and self-generated hydrogen.The 5 million euro boat is currently in a shipyard. It will set sail in Paris and make its first of 101 stops across 50 countries as part of a six-year circumnavigation.French environmentalists say the boat will demonstrate that there are many solutions for energetic transition, and all solutions are within nature.Designed in 1983, the boat enjoyed a successful career in open-sea sailing races. The Energy Observer project was conceived in 2015 by skippers, scuba divers and filmmakers.The technology fitted to the 30-meter boat will enable the production of hydrogen through the process of electrolysis. The boat is also equipped with a kite sail. It relies on the diversity of renewable energies. If there is no sun or wind, or at night, it has the option to draw in its hydrogen reservoirs. It will produce this hydrogen in a decarbonized manner through electrolysis of the sea water.This is Special English.Children with a genetic risk for obesity respond more strongly to fast food television advertising in a brain region associated with the reward processing. That&`&s according to a new study that may help understand why some children are more likely to over-eat unhealthy foods.The study is the first-of-its kind to examine how a key obesity gene influences brain response to food advertisements and other cues to eat. The gene is known as the fat-mass and obesity-associated, FTO, gene.The research was carried out by a team at the Dartmouth College, and the findings were published in the U.S. journal Proceeding of the National Academy of Sciences.In the study, 78 children, aged 9 to 12, watched a children&`&s television show in an magnetic resonance imaging scanner.To simulate the experience of watching television from home, the show included 12 minutes of commercial breaks, half were advertisements for fast food and the other half for non-food items.Children were also evaluated on their genetic risk for obesity based on the FTO gene, which strongly predicts obesity across the lifespan.The study found that the part of the brain which is commonly associated with reward craving is physically larger in children with the obesity-risk FTO genotype, compared to genetically low-risk children. In addition, this part of the brain also showed a stronger craving response to the food commercials in these children.You&`&re listening to Special English. I&`&m Ryan Price in Beijing. You can access the program by logging on to newsplusradio.cn. You can also find us on our Apple Podcast. If you have any comments or suggestions, please let us know by e-mailing us at mansuyingyu@cri.com.cn. That&`&s mansuyingyu@cri.com.cn. Now the news continues.Lethal overdoses on prescription painkillers in Australia have almost doubled in ten years. A new study published by Melbourne&`&s Penington Institute revealed that opioid-based painkillers were responsible for 71 per cent of all drug-related deaths in Australia in 2014.It also found that the use of opioid-based painkillers in Australia quadrupled between 2004 and 2014.The study shows that Australians aged 30-59 represented 78 per cent of all painkiller overdose deaths in the country.These figures have challenged the conventional wisdom that it is young urban people who are most at risk of dying of overdose in Australia.The study says it is now time for significant investments to be made to reduce the human toll from accidental overdose.Researchers said comprehensive investments have been made to reduce the road toll, and there should be similar level of investment being made into overdose prevention and awareness.Painkiller-related deaths were particularly prominent in rural areas, with 5 deaths per 100,000 people being attributed to painkiller overdoses in 2014. The figure marked an 83 per cent increase from the 3 deaths per 100,000 people recorded in 2004. This is Special English.A new study has found that urban sprawl is kicking one group of songbirds, called "avoiders", out of their territory, forcing divorce and stunting their ability to find new mates.The findings were the results of a 10 year research by John Marzluff, a professor of wildlife science in the University of Washington.Marzluff and his team monitored hundreds of individually marked songbirds from six common species found in suburbs of Seattle. The researchers tracked bird activity in different types of landscapes. Bands were placed around the birds&`& legs, and sightings of mated pairs and nest locations were mapped. The researchers were able to tell when a bird relocated, broke up from its mate or stayed put year to year.Avoider birds are species that are known to decline in response to urbanization, when forested areas are removed for developments. Monogamous birds will "divorce" their mate and move to a new territory if they have a reason to. When forced to move, the avoiders largely failed to reproduce again for at least one year after relocating. The whole transition to a new home and often a new partner might cause a bird to lose half of its breeding years.You&`&re listening to Special English. I&`&m Ryan Price in Beijing.Northwest China&`&s tourist city Xi&`&an is to appoint "toilet chiefs" this year, in an effort to improve services.The tourism bureau said the move aims to make all public toilets and those in restaurants and entertainment venues meet national standards, in terms of space and sanitation. All public toilets will also be free of charge.Xi&`&an is one the most popular tourist destinations in China. The city is planning to have private enterprises and individuals to run the toilets, which are currently under municipal administration.Toilet management will become part of the assessment for any tourist attractions and restaurants.China is in the middle of a three-year "toilet revolution", which includes building 35,000 new toilets across the country and renovating another 25,000 by the end of the year. This is Special English.China has a total of 700 million 4G mobile users, and the Ministry of Science and Technology says 5G commercial operations will be launched in 2020.The Ministry of Science and Technology said the 4G industrial chain has taken shape in China, with strengthened research and development capabilities.Wen said the ministry will promote the formation of a global unified 5G standard and push forward the use and innovation of 5G-based mobile Internet and the Internet of Things to lay a foundation for 5G commercial operations in 2020. This is Special English.More than 72,000 companies were offering language and translation services across China at the end of 2015.Among them, around 7,400 specialized in the field.According to a report on the development of China&`&s language service industry, the sector generated an output worth 280 billion yuan, roughly 41 billion U.S. dollars, in 2015.Experts say the development of information technology has presented brand new and huge opportunities for growth of language services.（全文见周日微信。）

UBS's Julian Emanuel weighs in on the healthcare sector after Abbott Laboratories announced plans to buy St. Jude Medical for about $25 billion on Bloomberg Surveillance with Michael McKee and David Gura. Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

Jason Drohn has been marketing online for 8 years, working with hundreds of businesses and thousands of entrepreneurs through his courses and done-for-you services.  He's best know for his ‘quickest path to cash' strategies where he cuts years of testing and development out of his client's lives, and delivers sales funnels that that are both automated and profitable Anthony Saccaro founder and president of Providence Financial & Insurance Services, is a financial planner and registered investment advisor- but is first and foremost an educator. For over 15 years, he has consulted with thousands of individuals about their finances. He is passionate about teaching and coaching clients on the universe of investment options in order to help them develop clear income strategies for a secure future. Saccaro is a frequent speaker on estate and financial planning topics and is an advisory board member for Senior Market Advisor, a leading industry publication Jack Uldrich renowned global futurist and bestselling author. He is an accomplished business speaker, addressing hundreds of businesses and organizations, including General Electric, General Mills, Pfizer, St. Jude Medical, and more. Jack presents complex information in an entertaining, understandable and digestible manner that stays with his audiences long afterwards. Jack speaks to business, nonprofit and educational audiences about future trends, emerging technologies, innovation, change, management and leadership. He is known for working with clients in advance in order to deliver tailored remarks that will educate, entertain and inspire his audiences  

Option Block 115: Scooping Cheap Volatility Trading Block: A volatility/VIX rundown -- it's up, it's down, it's in lockstep with the market, it does its own thing. It's VIX madness. Zenga, a new tech name to hit the market -- can it follow in the footsteps of Linkedin, Groupon, Angie's List or the other 2011 tech bubble names? A Metals/commodity rundown. Odd Block: Unusual activity in Norfolk Southern Corp. (NSC), St. Jude Medical, Inc. (STJ), and an Odd Block review from 10/27 on Hecla Mining Co. (HL).Xpress Block: Tim Navabi discusses the busy Friday expiration, taking calls from customers about deep in-the-money spreads and other goings on at OX.Around the Block: What are we watching this holiday week? Buffalo Wild Wing (BWLB) joins the Wheel of Fun, also game developer Take 2. It's a holiday week, so plan accordingly if you are long premium.